Trial demonstrates improved survival in metastatic non-small cell lung cancer patients using MK-1084 and pembrolizumab, suggesting a promising treatment alternative.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sacher et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: